Asaf Danziger - 01 Jan 2025 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Director
Signature
Steven Robbins, as attorney in fact for Danziger, Asaf
Issuer symbol
NVCR
Transactions as of
01 Jan 2025
Net transactions value
+$6,076
Form type
4
Filing time
03 Jan 2025, 16:04:05 UTC
Previous filing
06 Aug 2024
Next filing
01 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $6,076 +412 +2.7% $14.75 15,640 31 Dec 2024 Direct F1, F2
transaction NVCR Ordinary Shares Award $0 +400,000 +2558% $0.000000 415,640 01 Jan 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.
F3 Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates.